GemVax's Novel Peptide For Alzheimer’s Set To Advance After Positive Phase II

 
• By Jung Won Shin

GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
GemVax Has Advantage Not Having To Compete With Early Stage AD Drugs

More from R&D

More from Scrip